摘要：背景：肝脏特异的microRNA-122参与丙肝病毒复制，并且经评估它可作为潜在抗病毒干预的指标。然而，尚没有有关循环中的miR-122 在评估肝脏功能方面应用的报道。目前，关于血清学miRNA水平改变的评价最早出现在百草枯引起的急性肝中毒患者。方法：收集的血清标本使用实时反转录PCR分析。结果：显示血清miR-122和临床肝功指标丙氨酸转移酶存在正相关。此外，血清miR-122被用来评估乙型肝炎与肝细胞肝癌，发现在这两个紧密相关的疾病中，血清miR-122有明显的区别。除血清miR-122外，另一小细胞核RNA U6 在肝细胞肝癌患者被抑制，表明了其在这一疾病中的预后价值。结论：总之，这些证据表明血清miR-122 可以为不同的肝脏疾病提供标记物，更重要的是表明一个核酸标志物的组合 可被作为识别紧密相关疾病的一个敏感和特异的指标。
吉林大学第一医院肝胆胰内科 牛玲玲 摘译
本文首次发表于[Mol Med Report. 2012 Mar 15.]
Circulating microRNA-122 as a potential biomarker for liver injury
Abstract ：
Background：Liver-specific microRNA-122 (miR-122) is involved in the replication of hepatitis C virus (HCV) and its potential as a target for antiviral intervention was recently assessed. However, the use of circulating miR
Methods： Serum samples were collected and analyzed using real-time reverse transcription PCR.
Results：The results showed a positive correlation between serum miR-122 and alanine aminotransferase, a clinical biomarker for liver function. Furthermore, serum miR-122 was assessed in patients with hepatitis B and hepatocarcinoma, resulting in distinct miR-122 profiles in these two closely related diseases. In addition to miR-122, another small RNA, U6 small nuclear RNA, was downregulated in hepatocarcinoma patients, suggesting its prognostic significance in this disease.
Conclusion：Taken together, these lines of evidence indicate that serum miR-122 may provide a biomarker for diverse liver diseases and, more importantly, suggest that a combination of nucleic acid biomarkers may be used as a sensitive and specific index for discriminating closely related diseases.
